Subcutaneous infliximab CT-P13 without intravenous induction in psoriatic arthritis: A case report and pharmacokinetic considerations
CONCLUSION: SC infliximab was successfully used without previous IV infusion induction. Although, to date, the induction of PsA treatment via the SC route is not foreseen, the known pharmacokinetic properties and the outcome improvements observed in our patient show that subcutaneous treatment induction, as is already done in the treatment of rheumatoid arthritis, is also possible.PMID:38214148 | DOI:10.5414/CP204388
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Maria Chiara Ditto Simone Parisi Valentina Cotugno Diego Antonio Barila Luca Lo Sardo Francesco Cattel Enrico Fusaro Source Type: research
More News: Arthritis | Drugs & Pharmacology | Medical Ethics | Psoriatic Arthritis | Remicade | Rheumatoid Arthritis | Rheumatology